Our policy and aims
Anthony Nolan works with pharmaceutical companies in a variety of ways and several policies, which are underpinned by operational procedures and due diligence, ensure these relationships are conducted ethically. We have an overarching policy in place which governs how we work with pharmaceutical companies in a commercial and non-commercial capacity. If a relationship is commercial, it is subject to our usual due diligence procedures for working with third parties and is always subject to a contractual framework.
We always aim to be open, transparent, and honest in response to any public, supporter, patient or media enquiry concerning any of our relationships with pharmaceutical companies.
The total amount Anthony Nolan receives from the pharmaceutical industry in one financial year will not exceed 10% of our total income.
If our income from the industry would exceed 10% by agreeing to additional funding from a company or companies, then such a decision would require specific approval from the Chief Executive and the Board of Trustees.
The income Anthony Nolan has received from the pharmaceutical industry in FY 24/25 represents 1% of our total income (the same as the 1% of our total income in 23/24).
Anthony Nolan's non-commercial work with pharmaceutical companies in 2025
We would like to acknowledge the following non-commercial work with pharmaceutical companies in the last year:
- Astellas for its grant funding of £5,000 towards the overall cost of an Automated Haematology Analyser for the new Anthony Nolan Cell Collection Centre.
- Therakos UK (Mallinckrodt) for its grant funding of £110,000 towards our Patient Reported Outcomes Research, and £39,345 towards our Patient Grants Programme.
- Takeda UK Limited for its grant funding of £10,000 towards our Donor Recruitment Programme.
- Gilead Sciences Limited for its grant funding of £40,919.85 towards our CAR-T Health Care Professional Online E-Learning System.
- Johnson & Johnson for its grant funding of £19,000 towards our Cellular Therapy Clinical Nurse Specialist. We would also like to thank Johnson & Johnson for providing non-financial support to Anthony Nolan in the form of stand space at two J&J Haematology events for healthcare professionals, worth £250 each at both the Haem Summit and for Nurse Education Day.
- Anthony Nolan is also a member of various coalitions which receive funding from the pharmaceutical industry, including the Blood Cancer Alliance, Cancer52 and the Specialist Healthcare Alliance. Pharmaceutical funders of these organisations are listed on their respective websites: